Scientific Research

Research Into Homeopathy Part 25


Robert Medhurst presents part 25 in his series on research into homeopathy. The research includes humans, plants, animals and in vitro.

Past issues of this journal have carried news on the research into homeopathy that’s shown a positive outcome. What follows are summaries of more recently unearthed work that has been performed in this field.

Human Research

  1. Sevar R. Audit of outcome in 829 consecutive patients treated with homeopathic medicines. British Homeopathic Journal, 2000, 89, 4, 178-87.. In this study, consecutive patient files in a single homeopathic clinic were examined to determine the success or otherwise of this form of treatment. Of the 829 patients surveyed, 61% had a sustained improvement from their constitutional homeopathic treatment.
  1. Spence DS, Thompson EA, Barron SJ. Homeopathic treatment for chronic disease: a 6-year, university-hospital outpatient observational study. J Altern Complement Med, 2005, 11, 5, 793-8. This study looked at the effectiveness of individualised homeopathic therapy over a 6 year period in a UK homeopathic hospital outpatient department. The results from 6544 consecutive patients were examined, and when compared to baseline observations it was found that of these patients, 70% reported an improvement in their conditions.
  1. Stanton HE. Test and Anxiety- A Five Drop Solution. Education News, 1981, 17, 6, 12-15. In this trial, 40 students suffering from test-induced anxiety were given either homeopathic Argentum nitricum 12X or placebo. The level of test-induced anxiety was significantly reduced from the homeopathic medicine when compared to the placebo and this effect appeared to persist over time.
  1. Steinsbekk A, Ludtke R. Patients’ assessments of the effectiveness of homeopathic care in Norway: a prospective observational multicentre outcome study. Homeopathy, 2005, 94, 1, 10-6. In this prospective uncontrolled observational multi-centre outcome study, 654 people who’d visited 80 Norwegian homeopaths were asked to assess, via a Visual Analogue Scale (VAS) the effectiveness of this form of treatment comparing the VAS score at their first consultation with the VAS score 6 months later. After the results were collated it was found that 70% of those people visiting a Norwegian homeopath reported a meaningful improvement in their main complaint 6 months after the initial consultation.
  1. Trichard M, Chaufferin G, Nicoloyannis N. Pharmaco-economic comparison between homeopathic and antibiotic treatment strategies in recurrent acute rhinopharyngitis in children. Homeopathy, 2005, 94, 1, 3-9. In this 6 month prospective study involving 499 children suffering from acute rhinopharyngitis, the effectiveness, quality of life and cost of treatment with homeopathic (Group A) versus antibiotic (Group B) medicines, as prescribed by French medical practitioners, were assessed. Effectiveness, as measured by the numbers of episodes occurring subsequent to treatment, was 2.71 for Group A and 3.97 for Group B and quality of life as measured by the ParEnt-Qol scale was 21 for Group A versus 30 for Group B, which indicates a higher quality of life for those in Group A. In regard to costs, average direct medical costs were 88 Euros for Group A and 99 for Group B. Parental sick-leave affected 9.5% of the parents from Group A and 30% for Group B.
  1. Widrig R, et al. Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study. Rheumatol Int, 2007, 27, 6, 585-91. Using a double-blind protocol, 204 people suffering from radiologically confirmed and symptomatically active osteoarthritis were randomly assigned to receive either topical arnica or topical ibuprofen to be applied to the area where the condition was active. The success or failure of the treatments was assessed according to functional ability of the affected part and pain intensity in this area after 21 days of continuous treatment. Assessment of the results at the end of this period found that topical arnica was as successful as topical ibuprofen for the management of osteoarthritis.

Animal Research

  1. Varshney JP. Clinical management of idiopathic epilepsy in dogs with homeopathic Belladonna 200C: a case series. Homeopathy, 2007, 96, 1, 46-48. In this uncontrolled study, 10 dogs suffering from idiopathic epilepsy were given 3-4 drops of homeopathic Belladonna 200C during the seizure phase orally at 15min intervals until the seizure activity was reduced, and this was continued then four times daily. Four dogs with head shaking syndrome in addition to seizures were given an additional Cocculus 6C, 3-4 drops orally weekly for 3 months. As a result of this therapy, the numbers of fits reduced to 2-3 during first 2 weeks post-therapy and then became occasional in next 2 weeks. With continuation of Belladonna therapy, no fits were observed during 2-7 months follow-up. In two cases seizures reappeared within 15-25 days of cessation of therapy. Belladonna therapy was resumed and seizure control was again achieved. Owners were advised to continue the therapy at least twice daily until no fits occurred for at least 2 months.
  1. Varshney JP, Chaudhuri S. Atrial paroxysmal tachycardia in dogs and its management with homeopathic Digitalis–two case reports. Homeopathy, 2007, 96, 4, 270-2. Homeopathically prepared Digitalis 6C is a common prescription for those suffering from atrial tachycardia. This paper reports on the effects of Digitalis 6C, given at the Division of Medicine of the Indian Veterinary Research Institute in Izatnagar in India, to a Labrador dog and a German Shepherd dog, both of which were suffering from atrial paroxysmal tachycardia. Both dogs were given 4 drops of the medicine 4 times daily and their ECGs were assessed after 7 days of continuous treatment. At this point it was found that the heart rates of both dogs was stabilised and synchronized, with atrial and ventricular electrical activity appearing to be functioning normally.

Plant Research

  1. Fagan V, et al. High dilutions of Belladonna affect the mycelial growth of Corynespora cassiicola in vitro. Int J High Dilution Res, 2011, 10, 36, 245-248. Proceedings of the XXV GIRI Symposium and VIII CBFH; 2011, Sep, 04-07; Foz do Iguaçu (Brazil) 245. In this work from the State University of Maringá in Brazil, researchers sought to trial the use of homeopathically prepared Belladonna against the growth of spores from the fungus Corynespora cassiicola, which is associated with Target Spot disease, a problem that causes infection in various crops such as soybeans and is endemic to Brazil. This is a significant issue for organic farmers who are prohibited from using agricultural chemicals to control it. To test the effectiveness of this protocol, agar growth plates were produced and to these were added filtered Belladonna in 6X, 12X, 24X or 30X potencies or a filtered control (distilled water). The fungal isolate was peaked and grown and a disc of the fungal mycelia placed in the centre of each plate. The plates were incubated and checked daily for fungal growth from the disc for 12 days. The results showed that all of the potencies of Belladonna were effective in reducing the mycelial growth of the fungus when compared to control, with the best results achieved with the 30X potency.

In-Vitro Research

  1. Guimaraes F de SF, et al. In vitro and in vivo anticancer properties of a Calcarea carbonica derivative complex (M8) treatment in a murine melanoma model. BMC Cancer 2010, 10:113 doi:10.1186/1471-2407-10-113. This Brazilian study adds to previous work done to determine the anticancer effects of a combination product containing 10 homeopathically potentised substances, of which Calc carb 5C is the primary ingredient. B16F10 melanoma cells (a particularly aggressive cell line) in tissue culture were co-cultured with macrophages and lymphocytes. These were exposed to the homeopathic combination product and the results compared with an uninocculated control. On analysis it was shown that the homeopathic combination product was associated with an increase in the capacity of the lymphocytes in the tissue culture to destroy growing cancer cells, as well as an increase in the proportion of CD25+ lymphocytes and an increase in lymphocyte viability.

About the author

Robert Medhurst

Robert Medhurst BNat DHom DBM DRM DNutr is an Australian Naturopath & Homeopath with 40 years of clinical experience. He has written many articles and lectured on homeopathy throughout Australia and the U.S. Robert previously set up and operated 5 natural therapies practices in Sydney and Adelaide and was involved in teaching and medical research. He was formerly the Expert Advisor on Homeopathy to the Federal Government of Australia, Dept. of Health & Ageing. He specialises in homeopathy and is the author of The Business of Healing, the definitive guide for clinical practice establishment and management, as well as The Concordant Clinical Homeopathic Repertory. For more information see


  • I wonder (?) why the allopats do not make studies like these that Homeopathy do. They (allopats) dare to ignore these homeopathic studies, but they themselves do not present their results. Fear that their patients are getting worse and worse?

  • Thank you for this invaluable column. People should be aware that most of these homeopathy studies are not done by companies that stand to profit from them, as allopathic drug research is. One can rely in the results as being unbiased.

Leave a Comment